Pertuza (IV Infusion 420 mg/14 ml 14 ml vial)

Pertuza is a HER2/neu receptor antagonist indicated for: Use in combination with Trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease Use in combination with Trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival. Limitations of Use: The safety of Pertuza as part of a doxorubicin-containing regimen has not been established. The safety of Pertuza administered for greater than 6 cycles for early breast cancer has not been established. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Add to cart